JustWire.io

Mi., 24.06.2026 AstraZeneca

AstraZeneca and YMCA of the USA (Y-USA) announced today at the Aspen Ideas: Health conference, a five-year partnership focused on strengthening cancer education in the areas of screening and early detection to evidence-based programs helping cancer survivors living with, through and beyond cancer. This historic partnership brings together two in...

Newsfeed

AstraZeneca and YMCA of the USA Announce Landmark Partnership Aimed to Address Gaps in Cancer Care | AstraZeneca PLC

TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer | AstraZeneca PLC

Camizestrant Combination Delayed Time to First Progression by 55% and to Second Progression by 37% in Patients With Advanced HR-positive Breast Cancer With an Emergent ESR1 Tumor Mutation in SERENA-6 Trial | AstraZeneca PLC

IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) combined with lenvatinib and TACE reduced the risk of disease progression or death by 30% in embolization-eligible unresectable liver cancer in EMERALD-3 Phase III trial | AstraZeneca PLC

IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer | AstraZeneca PLC

DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US as first TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic triple-negative breast cancer who are not PD-1/PD-L1 inhibitor candidates | AstraZeneca PLC

AstraZeneca to showcase Phase III data in liver, breast and bladder cancers and potential first-in-class rare disease therapy at ASCO 2026 | AstraZeneca PLC

BAXFENDY approved in the US as the first and only aldosterone synthase inhibitor treatment for adults with hypertension | AstraZeneca PLC

ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US for two new indications for patients with HER2-positive early breast cancer | AstraZeneca PLC

Perioperative IMFINZI® (durvalumab) plus neoadjuvant EV showed statistically significant and clinically meaningful improvements in event-free survival and overall survival in muscle-invasive bladder cancer in the Phase III VOLGA trial | AstraZeneca PLC

TRUQAP® (capivasertib) recommended by FDA Advisory Committee for PTEN-deficient metastatic hormone-sensitive prostate cancer | AstraZeneca PLC

Pinetree Therapeutics Announces Exercise of Option to License EGFR Degrader Program by AstraZeneca | AstraZeneca PLC

AstraZeneca results: Q1 2026 | AstraZeneca PLC

BREZTRI approved in the US for asthma as first and only triple therapy for patients 12 years of age and older | AstraZeneca PLC

SAPHNELO approved in the US for subcutaneous self-administration as a new autoinjector for the treatment of systemic lupus erythematosus | AstraZeneca PLC

Tozorakimab met primary endpoint in Phase III MIRANDA trial in patients with COPD | AstraZeneca PLC

IMFINZI® (durvalumab) + IMJUDO® (tremelimumab-actl) improves PFS in early liver cancer | AstraZeneca PLC

Tozorakimab met primary endpoint in both OBERON and TITANIA Phase III trials in patients with COPD | AstraZeneca PLC

AstraZeneca and Joshua Jackson partner to encourage fans to Get Body Checked Against Cancer | AstraZeneca PLC

Koselugo approved in Canada for plexiform neurofibromas in adults with neurofibromatosis type 1 | AstraZeneca PLC

ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US as post-neoadjuvant treatment for patients with HER2-positive early breast cancer | AstraZeneca PLC

CALQUENCE® plus venetoclax approved in the US as first all-oral, fixed-duration combination for patients with chronic lymphocytic leukemia in the 1st-line setting | AstraZeneca PLC

XFRA: DIVIDEND/INTEREST INFORMATION - 20.02.2026 - GB0009895292 | AstraZeneca PLC

Positive and clinically meaningful results from the Phase III KALOS and LOGOS trials for BREZTRI in patients with uncontrolled asthma published in The Lancet Respiratory Medicine | AstraZeneca PLC

AstraZeneca awards $3.4 million for programs to improve access to healthcare for patients across the US | AstraZeneca PLC

AstraZeneca results: FY and Q4 2025 | AstraZeneca PLC

DATROWAY® (datopotamab deruxtecan-dlnk) granted Priority Review in the US as 1st-line treatment for patients with metastatic triple-negative breast cancer who are not candidates for immunotherapy | AstraZeneca PLC

AstraZeneca begins trading on the New York Stock Exchange | AstraZeneca PLC

XFRA: CAPITAL ADJUSTMENT INFORMATION - 02.02.2026 - GB0009895292 | AstraZeneca PLC

XETR: CAPITAL ADJUSTMENT INFORMATION - 02.02.2026 - GB0009895292 | AstraZeneca PLC

XFRA: CAPITAL ADJUSTMENT INFORMATION - 02.02.2026 - GB0009895292 | AstraZeneca PLC

Rick R. Suarez appointed US President and Head of US BioPharmaceuticals Business Unit | AstraZeneca PLC

ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Breakthrough Therapy Designation in the US as post-neoadjuvant therapy for patients with HER2-positive early breast cancer | AstraZeneca PLC

ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab approved in the US as first new treatment in a decade for the 1st-line treatment of patients with HER2-positive metastatic breast cancer | AstraZeneca PLC

AstraZeneca advances hematology and cell therapy ambition with largest-ever presence at ASH | AstraZeneca PLC

Baxdrostat New Drug Application accepted under FDA Priority Review in the US for patients with hard-to-control hypertension | AstraZeneca PLC

IMFINZI® approved in the US as first and only perioperative immunotherapy for patients with early gastric and gastroesophageal cancers | AstraZeneca PLC

AstraZeneca plans $2 billion manufacturing investment in Maryland, supporting 2,600 jobs and catalyzing economic growth | AstraZeneca PLC

Baxdrostat demonstrated a statistically significant and highly clinically meaningful placebo-adjusted reduction of 14.0 mmHg in 24-hour ambulatory systolic blood pressure in patients with resistant hypertension in the Bax24 Phase III trial | AstraZeneca PLC

Statistically significant NATRON Phase III trial results for hypereosinophilic syndrome show FASENRA delayed time to first flare or worsening of disease | AstraZeneca PLC

AstraZeneca's 9M and Q3 2025 Financial Results | AstraZeneca PLC

DATROWAY® (datopotamab deruxtecan-dlnk) demonstrated unprecedented median overall survival improvement of five months vs. chemo as 1st-line treatment for patients with metastatic triple-negative breast cancer for whom immunotherapy was not an option | AstraZeneca PLC

ENHERTU® (fam-trastuzumab deruxtecan-nxki) reduced the risk of disease recurrence or death by 53% vs. T-DM1 in patients with high-risk HER2-positive early breast cancer following neoadjuvant therapy in DESTINY-Breast05 Phase III trial | AstraZeneca PLC

ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by THP before surgery resulted in a pathologic complete response in 67% of patients with high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11 Phase III trial | AstraZeneca PLC

TEZSPIRE approved in the US for chronic rhinosinusitis with nasal polyps | AstraZeneca PLC

IMFINZI® (durvalumab) regimen reduced the risk of disease recurrence or death by 32% in high-risk non-muscle-invasive bladder cancer in the POTOMAC Phase III trial | AstraZeneca PLC

IMFINZI® (durvalumab)-based regimen reduced the risk of death by 22% in early gastric cancer vs. chemotherapy alone in MATTERHORN Phase III trial | AstraZeneca PLC

AstraZeneca unveils expanded manufacturing facility in Texas | AstraZeneca PLC

AstraZeneca furthers ambition to redefine cancer care with first data from four major pivotal trials at ESMO | AstraZeneca PLC

AstraZeneca plans to increase investment and scope of its Virginia manufacturing facility to $4.5 billion, creating 3,600 new jobs | AstraZeneca PLC